← Back to Clinical Trials
Recruiting NCT07396532

NCT07396532 Audio-Recorded Messages Delivered Via iPad to Prevent Delirium in Hip Fracture Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07396532
Status Recruiting
Phase
Sponsor Sengkang General Hospital
Condition Delirium - Postoperative
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2025-09-29
Primary Completion 2026-05

Eligibility & Interventions

Sex All sexes
Min Age 60 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Audio-Recorded Reorientation Intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2025-09-29 with a primary completion date of 2026-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this pilot clinical trial is to learn if personalized audio-recorded reorientation messages can be successfully implemented in general hospital wards for elderly patients after hip fracture surgery. It will also explore whether this intervention might help prevent confusion (delirium) after surgery. The main questions it aims to answer are: * Can the intervention be successfully delivered by nursing staff in a busy orthopedic ward? * How many eligible patients can be recruited and retained in the study? * Do patients tolerate listening to the personalized audio messages without problems? * Does listening to personalized audio messages show any early signs of reducing confusion after surgery? Researchers will compare patients who receive personalized audio messages to those who receive usual care to see if the intervention is feasible to implement and whether it shows promise for preventing delirium. Participants will: * Listen to 2-minute personalized audio-recorded reorientation messages played through an iPad and headphones three times daily for the first 3 days after surgery * Have their orientation and mental status checked daily for three times by nursing staff * Continue with all their regular medical care and treatments * Be monitored until discharge from the study wards.

Eligibility Criteria

Inclusion Criteria: * Older adults aged 60 years and above * Undergoing hip fracture repair surgery * No history of cognitive impairment as assessed by Abbreviated Mental Test (AMT) * Able to understand to any of the basic languages of Singapore (English, Malay, Mandarin, Tamil) Exclusion Criteria: * Patients not admitted directly to orthopaedic (study) wards post-operation (such as those requiring post-operative high-dependency unit care) * Patients managed conservatively without surgical intervention. * Patients admitted for periprosthetic hip fracture repairs * Patients who are deaf and mute

Contact & Investigator

Central Contact

Elaine Goh, RN, BSN

✉ elaine.goh.sh@skh.com.sg

📞 +65 82288624

Frequently Asked Questions

Who can join the NCT07396532 clinical trial?

This trial is open to participants of all sexes, aged 60 Years or older, studying Delirium - Postoperative. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07396532 currently recruiting?

Yes, NCT07396532 is actively recruiting participants. Contact the research team at elaine.goh.sh@skh.com.sg for enrollment information.

Where is the NCT07396532 trial being conducted?

This trial is being conducted at Singapore, Singapore.

Who is sponsoring the NCT07396532 clinical trial?

NCT07396532 is sponsored by Sengkang General Hospital. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology